A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Todd Michael Bauer, Mrinal M. Gounder, Amy M. Weise, Gary K. Schwartz, Richard D. Carvajal, Prasanna Kumar, Oleg Zernovak, Alida Beck, Jana Doyle, Jeanne Mendell-Harary, Jarema Peter Kochan, Shuquan Chen, Patricia LoRusso, William D. Tap, Neeta Somaiah, David Michael Hyman, Funda Meric-Bernstam, David S. Hong
Institutions: Sarah Cannon, Tennessee Oncology, Memorial Sloan Kettering Cancer Center, The Barbara Ann Karmanos Cancer Institute, Columbia University Irving Medical Center, Daiichi-Sankyo (Japan), Daiichi Sankyo (United States), Yale Cancer Center, Yale University, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890773677